Fidelity Investments
ACRV icon

Fidelity Investments’s Acrivon Therapeutics ACRV Stock Holding History

Fidelity Investments’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.4K Sell
6,957
-2,465
-26% -$4.19K ﹤0.01% 4829
2026
Q1 		$13.1K Buy
9,422
+800
+9% +$1.4K ﹤0.01% 4679
2025
Q4 		$20.8K Hold
8,622
– – ﹤0.01% 4448
2025
Q3 		$15.6K Sell
8,622
-1,228
-12% -$1.73K ﹤0.01% 4453
2025
Q2 		$11.7K Buy
9,850
+7,185
+270% +$9.86K ﹤0.01% 4486
2025
Q1 		$5.41K Sell
2,665
-268
-9% -$1.44K ﹤0.01% 4676
2024
Q4 		$17.7K Buy
2,933
+352
+14% +$2.56K ﹤0.01% 4231
2024
Q3 		$18.1K Buy
2,581
+933
+57% +$7.35K ﹤0.01% 4221
2024
Q2 		$9.56K Buy
1,648
+621
+60% +$5K ﹤0.01% 4345
2024
Q1 		$7.34K Buy
1,027
+221
+27% +$1.03K ﹤0.01% 4382
2023
Q4 		$3.97K Buy
806
+518
+180% +$2.74K ﹤0.01% 4513
2023
Q3 		$2.75K Sell
288
-134
-32% -$1.55K ﹤0.01% 4464
2023
Q2 		$5.47K Buy
422
+300
+246% +$3.63K ﹤0.01% 4340
2023
Q1 		$1.55K Buy
+122
New +$2.05K ﹤0.01% 4683

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments's ACRV Position: Q2 2026 in Review

Fidelity Investments reduced its Acrivon Therapeutics (ACRV) stake by 26% in Q2 2026, selling an estimated $4.19K and leaving 6,957 shares worth $12.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4829.

Fidelity Investments first reported a position in ACRV in Q1 2023 and has held it in 14 quarters since. The position peaked at $20.8K in Q4 2025. 46 funds tracked by Wall St. Rank hold ACRV as of Q2 2026.

  • Fidelity Investments held 6,957 shares of Acrivon Therapeutics worth $12.4K as of Q2 2026.
  • Fidelity Investments sold 2,465 Acrivon Therapeutics shares in Q2 2026, an estimated $4.19K.
  • Acrivon Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #4829 holding.
  • Fidelity Investments first reported a position in Acrivon Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Fidelity Investments's Acrivon Therapeutics position peaked at $20.8K in Q4 2025.
  • 46 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.